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PrePex Male Circumcision (MC) has been demonstrated as an effective and scalable strat-
egy to prevent HIV infection in low- and middle-income countries. This study describes the
follow-up and outcomes of clients who underwent PrePex MC between January 2011 and
December 2012 with weekly follow-up at the Rwanda Military Hospital, the first national hos-
pital in Rwanda to adopt PrePex.
Methods
Data on570 clients age 21 to 54 were extracted from patient records. We compared socio-
demographic and clinical characteristics, the operator's qualification, HIV status, pain
before and after device removal, urological status, device size and follow-up time between
clients who were formally discharged and those who defaulted. We reported bivariate asso-
ciations between each covariate and discharge status, number of people with adverse
events by discharge status, and time to formal discharge or defaulting using life table meth-
ods. Data were entered into Epidata and analyzed with Stata v13.
Results
Among study participants, 96.5% were circumcised by non-physician operators, 85.4%
were under 30years, 98.9% were HIV-negative and 97.9% were without any urological
problems that could delay the healing time. Most (70.7%) defaulted before formal discharge.
Pain before (p<0.001) and after PrePex device removal (p = 0.001) were associated with
discharge status, although very few cases were reported, and pain was more commonly
missing among defaulters. Twenty-seven adverse events were reported (7 formally
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discharged, 20 defaulters). Median follow-up time was seven weeks among formally dis-
charged and six weeks among defaulters (p<0.001).
Conclusion
Given that all socio-demographic and most clinical characteristics were not associated with
defaulting, we hypothesize that clients stopped returning once they determined they were
healed. We recommend less frequent follow-up protocols to encourage clinical visits until
formal discharge. Based on these results and recommendations, we believe PrePex MC is
a practical circumcision strategy in Rwanda and in sub-Saharan Africa.
Introduction
Surgical male circumcision(MC) is among the oldest surgical procedures worldwide[1], moti-
vated by various cultural, religious, hygienic and medical reasons [2]. Since the 1960s, MC has
been one of the most effective strategies to prevent sexually transmitted infections and to
address complications from sexual intercourse[1,3]. More recent observational and random-
ized controlled trials have shown that MC reduces the risk of HIV infection among adult males
by at least 50% [4,5]. The vast majority of all new HIV infections occur in sub-Saharan Africa
and 70% are due to heterosexual intercourse[4]. In this region, poverty, among other factors,
limits access to HIV prevention and treatment. As a result, WHO/UNAIDS recommends uni-
versal MC as a population-level HIV prevention strategy in countries with high HIV preva-
lence driven by heterosexual transmission and low male circumcision prevalence[4,6].
To have an impact on HIV transmission, WHO/UNAIDS set a target of 20 million men for
male circumcision in Africa by 2015[7]. Although surgery has been the most commonly used
MC procedure in adults, risks include bleeding, infections, mortality from anesthesia, and in
rare cases, complications that may lead to penile damage or sexual impotence[1,4]. Surgical
MC is a relatively time-intensive procedure performed in a sterile environment by a physician
using many instruments, with intensive care during the wound period[3,4].For these reasons,
surgical MC is not ideal for mass intervention in adult men in Africa due to limited resources
and few equipped health facilities and physicians[8].
In Rwanda, 3% of adults are infected with HIV, and only 13% of Rwandan men were cir-
cumcised in 2010[9]. In 2009, the Rwanda Ministry of Health set the target of 2 million adult
male circumcisions by the end of 2012[10].With only 1 physician per 16,000 inhabitants[11],
the Rwandan government considered alternatives to surgical MC including the Shang Ring
device [12] and the circular cutter with stapled anastomosis [13].The Ministry of Health opted
for PrePex, a quick, non-surgical procedure that does not require highly qualified staff or a ster-
ile environment [14]. With three clinical trials in Rwanda, the procedure was pre-qualified in
March 2012 by the WHO[10].Rwanda was the first country to adopt PrePex in the public
health setting on a mass scale.
There are several benefits to PrePex including the ability to shift the MC procedures to less-
trained staff, which makes the procedure cost-effective and scalable[15], even in high resource
settings[16].Further, the minimal invasiveness and risk make the procedure acceptable to bene-
ficiaries[17]. However, there is little research describing the implementation of PrePex in a real
world setting, outside of a research study environment. Rwanda Military Hospital (RMH), a
referral hospital in the country’s capital city, Kigali, which serves military members and civil-
ians (80% of patients) was the first hospital in the country to offer PrePex MC procedure
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starting in 2011. The goal of this paper is to describe the follow-up and outcomes of the first cli-
ents who underwent PrePex MC procedure at Rwanda Military Hospital (RMH).
Methods
Study design and population
This descriptive cross-sectional study included a retrospective review of records collected on
men age 21 to 54 receiving PrePex MC between January 2011 and December 2012 at RMH. To
receive PrePex MC, the client needed to demonstrate an ability to understand the study proce-
dures and requirements, comprehend and freely give informed consent, agree to abstain from
sexual intercourse following medical orders and agree to return to the health care facility for
follow-up visits.
PrePex procedure
The PrePex MC procedure is carried out in a clean environment, usually by a nurse, and takes
approximately five minutes. The device is comprised of three rings: the placement ring, inner
ring, and elastic ring. The procedure is comprised of the following steps: the client’s penis is
sized to select the appropriate device size, the operator disinfects and marks the foreskin where
the device should be placed, the elastic band is loaded onto the placement ring, the placement
ring is slid over the penis, the inner ring is placed inside of the foreskin and adjusted to the cir-
cumcision marking line, and finally the elastic ring is rolled from the placement ring into the
inner ring pressing the foreskin tightly. The procedure does not involve cutting live tissue,
anesthesia or sutures. After the PrePex ring is placed, the client continues to wear his clothes as
usual and embarks on his normal life. The ring is removed seven days after its placement when
the foreskin is necrotic. The dead tissue is removed with scissors, and any local wound from
the device removal is treated. In this study, the client was requested to return for weekly fol-
low-up visits until the wound was judged completely healed based on physical examination by
a trained operator; when the client was determined to have only a scar remaining he was for-
mally discharged from the program. The client was also instructed to return for any urgent
issues, regardless of the weekly follow-up visit schedule.
Data collection and analysis
This study used clinical records at RMH. Records were entered into Epidata by trained data
entry clerks under supervision of the University of Rwanda-College of Medicine and Health
Sciences-School of Public Health (UR-CMHS-SPH). Data quality was checked by looking for
outliers and comparing electronic and paper forms in outlier records.
We first explored the following factors in clients who were formally discharged versus those
who defaulted before formal discharge: age in years, qualification of the operator (nurse or phy-
sician), HIV status, urology history and status, level of pain reported before and after device
removal, adverse events any time after device placement, and the PrePex device size. Relation-
ships were assessed using the Fisher’s Exact test, and the follow-up time among the two groups
was measured using two-sample Wilcoxon-Mann-Whitney test; both at the α = 0.05 signifi-
cance level. Frequencies of adverse events (for all patients) and weeks of healing time (for
patients that formally discharged, the time between device placement and formal discharge)
were reported. The cumulative probability of the PrePex wound being healed or time to
defaulting was calculated using a life table approach. All analyses were completed in Stata v13.
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Ethics statement
At the first encounter, an operator explained the clinical procedure to the client and answered
any questions. Then the operator presented a written consent form in Kinyarwanda to the cli-
ent, and verbally explained its content: that information collected during medical visits related
to the PrePex procedure would be used in research, no identifying information about the client
would be published, and that the client had the option to receive the surgical procedure avail-
able countrywide in case he did not agree to participate in this study. A client provided a writ-
ten signature and checked a box for whether information could be shared, and he was provided
a copy of this signed consent form. The operator marked a yes/no check box in the medical
record indicating that consent was obtained, and a copy of the signed consent form was pro-
vided to the client. Clients’ confidentiality was secured by keeping paper records in a locked
cupboard with access only by authorized nurses. Data were entered in an electronic database
by trained data entry clerks at UR-CMHS-SPH, and no personal identifiers were electronically
recorded. All electronic data were stored on password protected computers held by the study
research team. This study protocol was approved by UR-CMHS-SPH Institutional Review
Board (ethical clearance number: 028/UR/CMHS/SPH/2014).
Results
Between January 2011 and December 2012, 639 men were screened for MC, 66 men did not
meet inclusion criteria, and 570 men received MC with PrePex at RMH. Among these clients,
167 (29.3%) were formally discharged and 403 (70.7%) defaulted before formal discharge.
Most clients were between 21 and 24 years old (57.7%) or 25 and 29 years (27.7%), and nearly
all clients were circumcised by a non-physician operator (97.0% and 96.3%, respectively,
among formally discharged and defaulters). Most men were HIV negative (99.4% among for-
mally discharged and 98.8% among defaulters) and had no evidence of urological problems
that could delay their healing and formal discharge (97.0% among formally discharged and
98.3% among defaulters). Very few men reported pain either before the device removal (0.5%)
or after the device removal (0.7%). Among all clients, 37.5% were fitted with the device size B
(28 mm), although, there was no statistical significant between the device size and defaulting
status (p = 0.725). Pain before (1.2% versus 0.3%) and after the device removal (0.6% versus
0.7%) were similar, but more clients were missing pain data among defaulters versus clients
who were formally discharged (p<0.001). The median follow-up time from device application
date was seven weeks (IQR: 5, 9) and six weeks (IQR: 1.8) respectively among formally dis-
charged and defaulter clients (p = 0.001) (Table 1).
Few adverse events were recorded (four cases of diffuse edema, four of bleeding, five of
wound infection, three of productive exudate and eleven others), of which20 (4.9%) were
among defaulters and seven (4.2%) were among formally discharged (Table 2). Most clients
healed between six and eight weeks (68.3%), very few (6.6%) required more than eight weeks to
heal; and seven adverse events occurred after the sixth week (Table 3).Most clients defaulted
between six and eight weeks (42.2%), few defaulted between nine and ten weeks (0.7%); and
four adverse events occurred between the second and fourth weeks, and 16 after the sixth week
(Table 4).
Discussion
The results of this real-world scale-up of PrePex MC at RMH are promising for the scale-up of
PrePex in other similar settings. In the first two years, 570 adult men were circumcised with
PrePex, primarily by non-physician staff. The few instances of adverse events and the recorded
healing times were consistent with larger clinical studies on PrePex where the median time for
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Table 1. Bivariate associations between discharge status and socio-demographic and clinical char-








n % n % N %
Overall 167 29.3 403 70.7 570 100
Age 0.555
21–24 97 58.1 232 57.6 329 57.7
25–29 50 29.9 108 26.8 158 27.7
30–34 11 6.6 44 10.9 55 9.7
35–39 6 3.6 14 3.5 20 3.5
40–44 3 1.80 3 0.7 6 1.1
45–54 0 0.0 1 0.3 1 0.2
Missing 0 0.0 1 0.3 1 0.2
Total 167 100.0 403 100.0 570 100.0
Operator's qualiﬁcation 0.225
Physicians 4 2.4 5 1.2 9 1.6
Non physicians 162 97.0 388 96.3 550 96.5
Missing 1 0.6 10 2.5 11 1.9
Total 167 100.0 403 100.0 570 100.0
HIV status 0.435
Positive 1 0.6 5 1.2 6 1.1
Negative 166 99.4 398 98.8 564 98.9
Total 167 100.0 403 100.0 570 100.0
Urology history 0.256
Urology problem 5 3.0 7 1.7 12 2.1
No urology problem 162 97.0 396 98.3 558 97.9
Total 167 100.0 403 100.0 570 100.0
Pain Before Device Removal <0.001
Yes 2 1.2 1 0.3 3 0.5
No 148 88.6 202 50.1 350 61.4
Missing 17 10.2 200 49.6 217 38.1
Total 167 100.0 403 100.0 570 100.0
Pain After Device Removal 0.001
Yes 1 0.6 3 0.7 4 0.7
No 166 99.4 378 93.8 544 95.4
Missing 0 0.0 22 5.5 22 3.9
Total 167 100.0 403 100.0 570 100.0
Adverse Event 0.189
Yes 7 4.2 20 4.9 27 4.7
No 160 95.8 375 93.1 535 1.4
Missing 0 0.0 8 2.0 8 93.9
Total 167 100.0 403 100.0 570 100.0
Device size 0.725
A(26 mm) 45 26.9 99 24.6 144 25.3
B(28 mm) 61 36.5 153 38.0 214 37.5
C(30 mm) 42 25.2 109 27.1 151 26.5
(Continued)
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healing was five to six weeks [18]. PrePex takes on average one to two weeks longer to heal
than surgical MC[19,20] or Shang ring[21].
The biggest challenge in this setting was the high rate of defaulting; a majority of patients
discontinued weekly follow-up visits before being formally discharged from the program. The
high rate of default during and after the sixth week might be because clients perceived that they
were healing properly and they did not feel a need to return for clinical assessments. We sus-
pect that a client with a significant problem would have come back for clinical follow-up.
Given the high rate of default before formal discharge, RMH is now using a protocol with less
frequent follow-up visits to improve adherence without compromising clinical outcomes.
The only socio-demographic or clinical difference between the groups was the amount of
missing data in reported pain before and after device removal. One explanation for this differ-
ence in missing data is that clients who defaulted tended to be the same types of clients who do
not respond to all questions during removal of the PrePex device. Another explanation is that
clients who were not asked about pain during device removal felt less rapport with clinical staff
and were more likely to default, though ongoing supervision of clinical staff throughout the
study makes this explanation unlikely.
The findings about adverse events among defaulters suggest that there were not substantial
differences in number, type, and timing of adverse events and experiences of pain between the
two groups which might drive someone to default. Other studies assessing the efficacy of Pre-
Pex procedure in a more formal study environment in Uganda and Rwanda also found few
adverse events among clients[14,17,18,22] and it is reassuring to see this continue in a real-
world setting. Given the low rate of adverse events and large amount of defaulting, implemen-









n % n % N %
D(32 mm) 15 9.0 30 7.4 45 7.9
E(34 mm) 1 0.8 8 2.0 9 1.6
Missing 3 1.8 4 1.0 7 1.2
Total 167 100.0 403 100.0 570 100.0
Follow-up time(median, IQR) 7 5,9 6 1,8 <0.001
doi:10.1371/journal.pone.0138287.t001
Table 2. Number of adverse events among those who defaulted and remained.
Types of adverse events Formally discharged Defaulted before formal discharge
Diffuse edema 1 3
Bleeding 1 3
Wound infection 1 4
Productive exudate 1 2
Other 3 8
Total 7(4.2% of 167 clients) 20(4.9% of 403 clients)
Note–one client may have multiple adverse events.
doi:10.1371/journal.pone.0138287.t002
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There are some limitations to this study. HIV, urological problems and adverse events were
all rare, and our sample may have been too small to detect differences between the defaulter
and non-defaulter groups. However, there is no indication of a difference between the groups
and we hypothesize that individuals are defaulting before formal discharge because they are
healing well. This should be studied more in the future. Additionally, although we collected
information about type of adverse event, information about the severity of adverse events was
not collected and should be collected in future studies. Finally, RMH is a national referral hos-
pital with different services and infrastructure compared to district hospitals and health centers
where this procedure is mostly likely to be scaled. However, as PrePex procedure is performed
in a clean environment, with non-physicians and without anesthesia, we expect that outcomes
and few complications observed in this study would be replicated in other clinical settings in
Rwanda and in sub-Saharan Africa.
Rwanda has been successful in implementing PrePex as a non-surgical MC procedure, a
strategy to supplement surgical MC to achieve the Ministry of Health target of two million
adult male circumcisions by 2012.However, the number of men circumcised in this two years
period at RMH is small compared to the two million targeted men; as of 2014, PrePex is only
implemented at RMH health facilities in Rwanda and during army weeks and RMH outreach
activities. Given these promising results, and that the procedure can be performed in a non-
sterile environment with a non-physician with very few adverse events, we strongly encourage
scale up of PrePex MC at all district hospitals in Rwanda. However, more evaluation of post
PrePex follow-up protocols should be conducted to encourage clinical monitoring of MC cli-
ents until full documented healing.
Table 3. Time and cumulative probability to formal discharge/healing(N = 167).








95% CI Timing and number of
adverse events
3–4 weeks 167 1 0.0600 0.0008 0.0417
4–5 weeks 166 1 0.0120 0.0030 0.0470
5–6 weeks 165 13 0.0898 0.0551 0.1446
6–7 weeks 152 57 0.4311 0.3601 0.5098 4
7–8 weeks 95 57 0.7725 0.7065 0.8327 2
8–9 weeks 38 27 0.9341 0.8897 0.9651
9–10 weeks 11 9 0.9880 0.9609 0.9976
10–11 weeks 2 2 1.0000 - - 1
doi:10.1371/journal.pone.0138287.t003
Table 4. Time and cumulative probability to defaulting (N = 403).








95% CI Timing and number of
adverse events
1–2 weeks 396 30 0.0758 0.0536 0.1066
2–3 weeks 366 58 0.2222 0.1844 0.2665 2
3–4 weeks 308 31 0.3005 0.2579 0.3483 2
4–5 weeks 277 25 0.3636 0.3184 0.4131
5–6 weeks 252 44 0.4747 0.4269 0.5251
6–7 weeks 208 88 0.6970 0.6513 0.7415 7
7–8 weeks 120 82 0.9040 0.8726 0.9305 6
8–9 weeks 38 35 0.9924 0.9793 0.9979 3
9–10 weeks 3 3 1.0000 - -
doi:10.1371/journal.pone.0138287.t004
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